The Role of Medicaid Expansion on the Receipt of Adjuvant Chemotherapy in Patients With Lung Cancer
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2024.09.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Hamza Rshaidat und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Esophageal and Thoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, 19107. Hauptthemen laut MEDLINE: Medicaid, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVE: We aimed to utilize a nationally representative database to study the effect of Medicaid expansion on the receipt of adjuvant chemotherapy in eligible patients. MATERIALS AND METHODS: Retrospective review of the National Cancer Database (NCDB) was performed between 2006 and 2019. Patients with clinical T1-T3, N1, and M0 were included. Patients with nodal disease or tumors > 4 cm were eligible for adjuvant therapy. Demographic and clinical information were collected. A difference-in-difference analysis was performed to compare changes in the rate of adjuvant chemotherapy. RESULTS: Total 9954 eligible patients were treated in states that expanded Medicaid coverage in January 2014 or later, with 4809 patients treated in the pre-expansion years (2012-2013) and 5145 patients treated in the postexpansion years (2017-2018). Following Medicaid expansion, eligible patients were more likely to receive adjuvant therapy (70.2% vs. 62.3%; P < .001). Compared with the pre-expansion period, patients who received adjuvant therapy were more likely to use Medicaid insurance postexpansion (7.8% vs. 5%, P < .001). Among patients using Medicaid coverage only, a greater percentage started adjuvant therapy within 8 weeks of resection following Medicaid expansion (46.6% vs. 38.3%, P = .048). The observed difference-in-difference in the change in adjuvant therapy rate from the pre-expansion period to the postexpansion period between expansion and nonexpansion states was 1.25% (95% Bootstrap CI -0.36% to -3.18%). There was a modest survival benefit in expansion states postexpansion. CONCLUSION: Medicaid expansion appears to be associated with increased access to care, as shown by the increased receipt of adjuvant systemic therapy in eligible patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Esophageal and Thoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, 19107.
- Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107.
- Department of Pharmacology, Physiology and Cancer Biology, Division of Biostatistics and Bioinformatics, Sidney Kimmel Medical College, Philadelphia, PA, 19107.
- Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, 19107.
- Department of Surgery, Division of Esophageal and Thoracic Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, 19107. Electronic address: Olugbenga.Okusanya@jefferson.edu.
Zitieren
APA
Rshaidat, H., Mack, S. J., Koeneman, S. H., Martin, J., Whitehorn, G. L., Madeka, I., Gordon, S. W., & Okusanya, T. O. T. (2025). The Role of Medicaid Expansion on the Receipt of Adjuvant Chemotherapy in Patients With Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.09.007
Vancouver
Rshaidat H, Mack SJ, Koeneman SH, Martin J, Whitehorn GL, Madeka I, et al. The Role of Medicaid Expansion on the Receipt of Adjuvant Chemotherapy in Patients With Lung Cancer. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2024.09.007
BibTeX
@article{Rshaidat2025,
author = {Rshaidat, Hamza and Mack, Shale J and Koeneman, Scott H and Martin, Jonathan and Whitehorn, Gregory L and Madeka, Isheeta and Gordon, Sarah W and Okusanya, T Olugbenga T},
title = {The Role of Medicaid Expansion on the Receipt of Adjuvant Chemotherapy in Patients With Lung Cancer},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2024.09.007}
}
EUVIMED